Sign In
Buy 0HNC
Biomarin Pharmaceutical Earnings Calls
| Release date | Oct 27, 2025 |
| EPS estimate | -$0.265 |
| EPS actual | -$0.160 |
| EPS Surprise | 39.64% |
| Revenue estimate | 823.535M |
| Revenue actual | 776.133M |
| Revenue Surprise | -5.76% |
| Release date | Aug 04, 2025 |
| EPS estimate | $0.86 |
| EPS actual | $1.22 |
| EPS Surprise | 41.70% |
| Revenue estimate | 806.594M |
| Revenue actual | 827.473M |
| Revenue Surprise | 2.59% |
| Release date | May 01, 2025 |
| EPS estimate | $0.682 |
| EPS actual | $0.95 |
| EPS Surprise | 39.30% |
| Revenue estimate | 762.438M |
| Revenue actual | 745.145M |
| Revenue Surprise | -2.27% |
| Release date | Feb 19, 2025 |
| EPS estimate | $0.534 |
| EPS actual | $0.636 |
| EPS Surprise | 19.10% |
| Revenue estimate | 728.742M |
| Revenue actual | 738.222M |
| Revenue Surprise | 1.30% |
Last 4 Quarters for Biomarin Pharmaceutical
Below you can see how 0HNC.L performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 19, 2025 |
| Price on release | $64.91 |
| EPS estimate | $0.534 |
| EPS actual | $0.636 |
| EPS surprise | 19.10% |
| Date | Price |
|---|---|
| Feb 13, 2025 | $64.70 |
| Feb 14, 2025 | $64.18 |
| Feb 17, 2025 | $64.29 |
| Feb 18, 2025 | $65.42 |
| Feb 19, 2025 | $64.91 |
| Feb 20, 2025 | $68.88 |
| Feb 21, 2025 | $69.98 |
| Feb 24, 2025 | $68.78 |
| Feb 25, 2025 | $70.51 |
| 4 days before | 0.325% |
| 4 days after | 8.62% |
| On release day | 6.12% |
| Change in period | 8.97% |
| Release date | May 01, 2025 |
| Price on release | $62.92 |
| EPS estimate | $0.682 |
| EPS actual | $0.95 |
| EPS surprise | 39.30% |
| Date | Price |
|---|---|
| Apr 25, 2025 | $62.81 |
| Apr 28, 2025 | $63.38 |
| Apr 29, 2025 | $63.61 |
| Apr 30, 2025 | $63.03 |
| May 01, 2025 | $62.92 |
| May 02, 2025 | $61.27 |
| May 05, 2025 | $62.25 |
| May 06, 2025 | $61.18 |
| May 07, 2025 | $59.50 |
| 4 days before | 0.175% |
| 4 days after | -5.44% |
| On release day | -2.62% |
| Change in period | -5.27% |
| Release date | Aug 04, 2025 |
| Price on release | $58.77 |
| EPS estimate | $0.86 |
| EPS actual | $1.22 |
| EPS surprise | 41.70% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $58.18 |
| Jul 30, 2025 | $59.30 |
| Jul 31, 2025 | $58.36 |
| Aug 01, 2025 | $57.63 |
| Aug 04, 2025 | $58.77 |
| Aug 05, 2025 | $62.96 |
| Aug 06, 2025 | $61.01 |
| Aug 07, 2025 | $59.52 |
| Aug 08, 2025 | $56.31 |
| 4 days before | 1.01% |
| 4 days after | -4.19% |
| On release day | 7.13% |
| Change in period | -3.21% |
| Release date | Oct 27, 2025 |
| Price on release | $54.88 |
| EPS estimate | -$0.265 |
| EPS actual | -$0.160 |
| EPS surprise | 39.64% |
| Date | Price |
|---|---|
| Oct 21, 2025 | $53.33 |
| Oct 22, 2025 | $54.15 |
| Oct 23, 2025 | $54.09 |
| Oct 24, 2025 | $54.57 |
| Oct 27, 2025 | $54.88 |
| Oct 28, 2025 | $54.02 |
| Oct 29, 2025 | $53.06 |
| Oct 30, 2025 | $52.31 |
| Oct 31, 2025 | $52.26 |
| 4 days before | 2.91% |
| 4 days after | -4.77% |
| On release day | -1.57% |
| Change in period | -2.01% |
Biomarin Pharmaceutical Earnings Call Transcript Summary of Q3 2025
BioMarin reported strong Q3 2025 performance driven by Enzyme Therapies and the Skeletal Conditions business (VOXZOGO). Year-to-date total revenue grew 11% versus 2024. Management raised the lower end of full‑year 2025 total revenue guidance (midpoint implies double-digit growth) and reaffirmed VOXZOGO 2025 revenue guidance of $900M–$935M. Q3 included a $221M pretax IPR&D charge related to the July Inozyme acquisition, which reduced reported operating margin and EPS for the quarter but did not change underlying cash generation — operating cash flow was $369M in Q3 and $728M year-to-date, leaving ~ $2.0B in cash and investments at quarter end. BioMarin announced it is pursuing options to divest ROCTAVIAN to focus on prioritized business units. Key near-term R&D and commercial milestones: Phase III readout for VOXZOGO in hypochondroplasia expected H1 2026 (potential 2027 launch), initiation of Phase II/III for BMN 333 H1 2026, potential PALYNZIQ adolescent label updates in 2026, and Phase III data for BMN 401 H1 2026. Management outlined scenario-based 2027 revenue modeling rather than a single point forecast due to uncertainties (notably potential VOXZOGO competition) and reiterated a target of ~40% non‑GAAP operating margin for 2026 while prioritizing value-creating investments. Business development remains a top capital allocation priority; total estimated deployment firepower is ~$4B–$5B.
